摘要
目的:研究达比加群酯联合双联抗血小板药物应用于非瓣膜性房颤患者经皮冠状动脉介入治疗(PCI)术后的效果。方法:选取2018年10月至2019年10月期间漯河市第六人民医院收治的非瓣膜性房颤患者86例,按照随机数字表法分为对照组、观察组,各43例。两组均行PCI术,并给予阿司匹林、氯吡格雷双联抗血小板治疗,对照组采用华法林治疗,观察组采用达比加群酯治疗。比较两组治疗前、治疗6个月后凝血功能[凝血酶时间(TT)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)]、血栓弹力图指标[凝血因子反应时间(R值)、Angle角、MA值]及终点事件发生率。结果:治疗6个月后观察组TT、APTT、PT长于对照组(P<0.05);治疗6个月后两组Angle角、MA值比较,差异无统计学意义(P>0.05);治疗6个月后观察组R值大于对照组(P<0.05);观察组终点事件发生率4.65%低于对照组20.93%(P<0.05)。结论:达比加群酯联合双联抗血小板药物应用于非瓣膜性房颤患者PCI术后能改善凝血功能,提高R值,降低终点事件发生率。
Objective:To study the effect of dabigatran axetil combined with dual antiplatelet drugs in patients with nonvalvular atrial fibrillation after percutaneous coronary intervention(PCI).Methods:86 patients with nonvalvular atrial fibrillation admitted to the Sixth People's Hospital of Luohe City from October 2018 to October 2019 were selected and randomly divided into control group and observation group,43 cases in each group.The two groups were treated with PCI and given aspirin and clopidogrel dual antiplatelet therapy.The control group was treated with warfarin,and the observation group was treated with dabigatran axetil.The coagulation function[thrombin time(TT),activated partial thromboplastin time(APTT),prothrombin time(PT)],thromboelastogram indexes[coagulation factor response time(R value),Angle angle,Ma value]and the incidence of end-point events were compared between the two groups before and after 6 months of treatment.Results:After 6 months of treatment,TT,APTT and PT in the observation group were longer than those in the control group(P<0.05);after 6 months of treatment,there was no significant difference in Angle angle and Ma between the two groups(P>0.05);after 6 months of treatment,the R value of the observation group was higher than that of the control group(P<0.05);the incidence of end-point events in the observation group was 4.65%lower than that in the control group 20.93%(P<0.05).Conclusion:Dabigatran cilexetil combined with dual antiplatelet drugs in patients with nonvalvular atrial fibrillation after PCI can improve coagulation function,increase R value and reduce the incidence of end-point events.
作者
张庆
张华杰
杨杰
ZHANG Qing;ZHANG Huajie;YANG Jie(Luohe Sixth People's Hospital,Luohe Henan 462000,China)
出处
《药品评价》
CAS
2021年第3期175-177,共3页
Drug Evaluation
作者简介
张庆,本科,主治医师。研究方向:心血管内科。E-mail:zhang15890220787@126.com。
